Targeting Mcl-1 Enhances the Activity of Tyrosine Kinase Inhibitor Gilteritinib in FLT3 Mutated AML

被引：1

作者：

Carter, Bing Z.

Mak, Po Yee

Ruvolo, Vivian

Tao, Wenjing

Hughes, Paul

Chen, Xiaoyue

Morrow, P. K.

Andreeff, Michael

机构：

来源：

BLOOD | 2020年 / 136卷

关键词：

D O I：

10.1182/blood-2020-141399

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[31] Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1 [J].

Janssen, Maike ;

Schmidt, Christina ;

Bruch, Peter-Martin ;

Blank, Maximilian F. ;

Rohde, Christian ;

Waclawiczek, Alexander ;

Heid, Daniel ;

Renders, Simon ;

Goellner, Stefanie ;

Vierbaum, Lisa ;

Besenbeck, Birgit ;

Herbst, Sophie A. ;

Knoll, Mareike ;

Kolb, Carolin ;

Przybylla, Adriana ;

Weidenauer, Katharina ;

Ludwig, Anne Kathrin ;

Fabre, Margarete ;

Gu, Muxin ;

Schlenk, Richard F. ;

Stoelzel, Friedrich ;

Bornhaeuser, Martin ;

Roellig, Christoph ;

Platzbecker, Uwe ;

Baldus, Claudia ;

Serve, Hubert ;

Sauer, Tim ;

Raffel, Simon ;

Pabst, Caroline ;

Vassiliou, George ;

Vick, Binje ;

Jeremias, Irmela ;

Trumpp, Andreas ;

Krijgsveld, Jeroen ;

Mueller-Tidow, Carsten ;

Dietrich, Sascha .

BLOOD, 2022, 140 (24) :2594-2610

[32] Plm-102, a Next Generation FLT3 Inhibitor, Shows Potent Anti-Leukemic Activity on Resistance to Gilteritinib in FLT3 Mutated Acute Myeloid Leukemia [J].

Lee, Jae-Seon ;

Park, Min Ji ;

Sun, Ningning ;

Park, Jin-Hee ;

Oh, Su-jin ;

Moon, Miran ;

Kim, Myung Jin ;

Jang, Soo Yeon ;

Kim, Yong-Chul .

BLOOD, 2023, 142

[33] BMX kinase mediates gilteritinib resistance in FLT3-mutated AML through microenvironmental factors [J].

Buelow, Daelynn R. ;

Bhatnagar, Bhavana ;

Orwick, Shelley J. ;

Jeon, Jae Yoon ;

Eisenmann, Eric D. ;

Stromatt, Jack C. ;

Pabla, Navjot Singh ;

Blachly, James S. ;

Baker, Sharyn D. ;

Blaser, Bradley W. .

BLOOD ADVANCES, 2022, 6 (17) :5049-5060

[34] Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML [J].

Jiang, JR ;

Paez, JG ;

Lee, JC ;

Bo, RH ;

Stone, RM ;

DeAngelo, DJ ;

Galinsky, I ;

Wolpin, BM ;

Jonasova, A ;

Herman, P ;

Fox, EA ;

Boggon, TJ ;

Eck, MJ ;

Weisberg, E ;

Griffin, JD ;

Gilliland, DG ;

Meyerson, M ;

Sellers, WR .

BLOOD, 2004, 104 (06) :1855-1858

[35] Combination Therapy of FLT3 Tyrosine Kinase Inhibitors and BH3 Mimetics Targeting Antiapoptotic MCL-1 Synergistically Eliminates FLT3-ITD Acute Myeloid Leukemia Cells in Vitro and In Vivo [J].

Skwarska, Anna ;

Moujalled, Donia M. ;

Panis, Paul F. ;

Patel, Shraddha ;

Zhang, Qi ;

Herbrich, Shelley ;

Kurvilla, Vinitha ;

Baran, Natalia ;

Pomilio, Giovanna ;

Halilovic, Ensar ;

Mistry, Prakash ;

Ruvolo, Vivian ;

Ruvolo, Peter P. ;

Derreal, Alix ;

Banquet, Sebastien ;

Niemira, Magdalena ;

Kretowski, Adam ;

Daver, Naval ;

Andreeff, Michael ;

Wei, Andrew H. ;

Konopleva, Marina .

BLOOD, 2021, 138

[36] Correction to: Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor [J].

Angela Joubert James ;

Catherine C. Smith ;

Mark Litzow ;

Alexander E. Perl ;

Jessica K. Altman ;

Dale Shepard ;

Takeshi Kadokura ;

Kinya Souda ;

Melanie Patton ;

Zheng Lu ;

Chaofeng Liu ;

Selina Moy ;

Mark J. Levis ;

Erkut Bahceci .

Clinical Pharmacokinetics, 2021, 60 :1251-1251

[37] FLT3 and KIT mutated pediatric acute myeloid leukemia (AML) samples are more sensitive in vitro to the tyrosine kinase Inhibitor SU11657. [J].

Goemans, Bianca F. ;

Zwaan, Christian M. ;

de Lange, Desiree ;

Cloos, Jacqueline ;

Reinhardt, Dirk ;

Hahlen, Karel ;

Gibson, Brenda E. S. ;

Creutzig, Ursula ;

Kaspers, GertJan J. L. .

BLOOD, 2006, 108 (11) :397A-397A

[38] Discovery of a highly potent FLT3 kinase inhibitor for FLT3-ITD-positive AML [J].

Wu, H. ;

Wang, A. ;

Qi, Z. ;

Li, X. ;

Chen, C. ;

Yu, K. ;

Zou, F. ;

Hu, C. ;

Wang, W. ;

Zhao, Z. ;

Wu, J. ;

Liu, J. ;

Liu, X. ;

Wang, L. ;

Wang, W. ;

Zhang, S. ;

Stone, R. M. ;

Galinsky, I. A. ;

Griffin, J. D. ;

Weinstock, D. ;

Christodoulou, A. ;

Wang, H. ;

Shen, Y. ;

Zhai, Z. ;

Weisberg, E. L. ;

Liu, J. ;

Liu, Q. .

LEUKEMIA, 2016, 30 (10) :2112-2116

[39] FLT3 Inhibitor Treatment in FLT3-Mutated AML Is Associated with Development of Secondary FLT3-TKD Mutations [J].

Alvarado, Yesid ;

Kantarjian, Hagop M. ;

Ravandi, Farhad ;

Luthra, Rajyalakshmi ;

Borthakur, Gautam ;

Manero, Guillermo Garcia ;

Faderl, Stefan ;

Konopleva, Marina ;

Estrov, Zeev ;

Andreeff, Michael ;

Cortes, Jorge E. .

BLOOD, 2011, 118 (21) :648-648

[40] Discovery of a highly potent FLT3 kinase inhibitor for FLT3-ITD-positive AML [J].

H Wu ;

A Wang ;

Z Qi ;

X Li ;

C Chen ;

K Yu ;

F Zou ;

C Hu ;

W Wang ;

Z Zhao ;

J Wu ;

J Liu ;

X Liu ;

L Wang ;

W Wang ;

S Zhang ;

R M Stone ;

I A Galinsky ;

J D Griffin ;

D Weinstock ;

A Christodoulou ;

H Wang ;

Y Shen ;

Z Zhai ;

E L Weisberg ;

J Liu ;

Q Liu .

Leukemia, 2016, 30 :2112-2116

← 1 2 3 4 5 →